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Rationale: Even in stable asthma patients, acinar ventilation distribution can be abnormal,
and we aimed to specifically maximize its reversibility by switching patients from a standard
inhaled corticosteroid (iCS) to a fine particle iCS formulation.
Methods: For this prospective double-blind double-dummy randomized study, 66 stable asthma
patients under maintenance iCS (equivalent budesonide  800 mg/day) were screened for
abnormal baseline acinar ventilation heterogeneity (Sacin). After a 3-week run-in period, 35
eligible patients were randomized to fine particle beclomethasone (HFA-BDP; Qvar Autohaler)
or to budesonide (DPI-BUD; Pulmicort Turbohaler). Asthma Control Test (ACT) score and
various lung function indices reflecting the small airways were obtained at baseline, after 6
and 12 weeks.
Results: Thirty one patients [age:52  17(SD) years; FEV1:76  19(SD)%pred] completed the
study (DPI-BUD:n Z 16; HFA-BDP:n Z 15). After 6 and 12 weeks, there were no significant
changes in acinar or conductive ventilation heterogeneity, nor in mid-expiratory flow, RV/
TLC, closing capacity, impulse oscillometry indices (resistance, reactance), bronchial NO pro-
duction or alveolar NO, in either treatment arm. Asthma control was maintained in both arms.
Conclusion: In stable asthma patients with small airways dysfunction under maintenance ther-
apy, there is a residual functional abnormality in the lung periphery which is probably not
eosinophilic in origin and cannot be normalized with the iCS formulations under study.
ISRCTN17195095.
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Imaging and physiological studies have shown that asthma
patients may be subject to morphometric and functional
changes in the small airways, including the acinar airways
[1]. Clinical studies have also shown that in asthma pa-
tients, ventilation heterogeneity in the peripheral lung
zone correlates with asthma control [2]. Very recently,
asthma severity has been shown to correlate with increased
acinar ventilation heterogeneity [3]. In patients with a
marked baseline abnormality in acinar ventilation hetero-
geneity, this heterogeneity could be partly reduced by
small particle steroid aerosols, while patients with normal
baseline acinar heterogeneity were unaffected by steroid
particle size [4]. In those patients displaying reversibility of
acinar heterogeneity, reversibility was of the order of 20%,
with considerable residual abnormality persisting. Since no
inflammatory markers were obtained in that study, it was
impossible to know whether this residual small airway
dysfunction was inflammatory in origin. Other studies using
alveolar nitric oxide as an outcome parameter, have
observed decreases in alveolar nitric oxide following small
particle steroid formulations in relatively mild asthma or
with systemic treatment in mild-to-moderate refractory
asthma [5]. Alveolar nitric oxide has also been shown to be
weakly associated with acinar ventilation heterogeneity, at
least in asthma patients on a maintenance treatment
exceeding 500 mg BDP equivalent per day [6].
In the present work we aimed to promote reversibility of
acinar airway function in asthma patients with abnormal
acinar ventilation heterogeneity at baseline, despite being
clinically stable.Theway toachieve thiswas to screenasthma
patients for increased baseline acinar ventilation heteroge-
neity, and have them switched from a standard inhaled
corticosteroid (iCS) to a fine particle iCS formulation. While
ventilation heterogeneity in the acinar airways was the pri-
mary outcome measure, we also examined several other
physiological indices reflecting other aspects of small airways
function, suchas alveolar nitric oxide, frequencydependence
of resistance and plethysmographic volumes [7]. All mea-
surements were done at baseline, following 3 weeks of
reference medication, 6 weeks after introducing study
medication, and after another 6 weeks of study medication.
In order to specifically study the inflammatory compo-
nent of acinar ventilation heterogeneity, we isolated the
corticosteroid from the long acting beta-agonist (LABA) by
administering the inhaled steroid, either in standard or fine
particle formulation, separately from the LABA. Given the
commercial availability of inhaler devices and the double-
dummy design, the iCS and LABA inhalation by separate
devices required a considerable number of puffs. To avoid
the risk of non-compliance or error due to the number of
puffs, the present study included only asthma patients on
800 mg equivalent BUD dose or less per day.
Materials and methods
Study subjects
The study protocol was approved by the local ethics com-
mittee and registered in the ISCRTN clinical trials database(ISCRTN17195095). Recruitment took place in the respira-
tory outpatient clinic of a university hospital among non-
smokers with physician-documented asthma. In order to be
eligible for a screening visit, asthma patients had not
experienced any asthma exacerbations in the previous 6
months. They were clinically stable under a maintenance
ICS dose of 800 mg BUD equivalent per day and had not
had any change in medication during the previous 3
months. After giving their informed consent, asthma pa-
tients were screened for acinar ventilation heterogeneity
by means of the Multiple Breath nitrogen Washout (MBW)
test and included in the study only if Sacin, the MBW
parameter reflecting acinar ventilation heterogeneity and
the primary outcome variable, exceeded 0.12 L1. This cut-
off value, as well as the number of patients to be recruited
for this study was based on our previous study [4]. We
aimed to recruit 35 patients in order to ensure full data
sets on all visits on at least 15 patients in each treatment
arm.
Study design
This study was conducted in a double blind fashion and
because of differences in commercially available inhalers
devices, a double dummy design had to be applied, inflating
the number of inhalations needed per day. After inclusion
and careful instruction on the use of the different inhalers,
a 3-week run in period started, during which all patients
were treated with the reference medication (DPI-BUD;
Turbohaler) at a dose equipotent to their maintenance iCS
dose, based on equivalence tables [8]. At the second visit,
participants were randomized to either the fine particle iCS
treatment group receiving an equipotent dose of HFA-BDP
[8] or to the control group remaining on the reference
DPI-BUD treatment. For those patients previously treated
with a long acting b2 agonist (LABA) in combination with
iCS, LABA treatment was continued at the same dosage
with separate inhalers throughout the study. After
randomization, study visits for complete lung function
testing were scheduled at baseline, 6 and 12 weeks later
(Fig. 1). At each study visit, patients completed an Asthma
Control Test (ACT) and after a baseline spirometry, bron-
chodilation was induced by 400 mg salbutamol (inhaled with
Volumatic spacer). Ten minutes later, the following
sequence of lung function tests were initiated: exhaled NO
measurements, spirometry, body plethysmography, MBW
testing, and impulse oscillometry.
Methods
Lung function measurements were obtained by means of
standardized equipment (Vmax20C, CardinalHealth, Bilt-
hoven, The Netherlands) according to recommendations [9]
or by validated custom-built equipment previously
described for exhaled NO measurements [6], impulse
oscillometry [10] and MBW testing [11] in our laboratory.
For spirometry and plethymography the 1993 ERS reference
values [9] were used. For the MBW parameters (with the
primary outcome variable Sacin), a recent report with
reference values in the age range 25e65years [11] could
now be used to obtain predicted values.
Figure 1 Schematic representation of the study schedule.
After a 3 week run-in period on DPI-BUD, patients are ran-
domized to either the study group (HFA-DBP) or to the control
group (DPI-BUD) for 12 weeks.
Acinar airway abnormality in asthma 1603Parameters included
(1) exhaled NO: by measuring exhaled NO at expiratory
flows between 100 and 350 ml s1, and using the
regression method of Pietropaoli [12] and the back
diffusion correction method by Kerckx et al. [13], we
obtain bronchial NO production [J’aw(pl/s)] and
alveolar NO concentration (Calv) with or without back
diffusion correction; exhaled NO measured at
50 ml s1 (FENO50) was also recorded;
(2) Spirometry: forced expiratory volume in 1 s (FEV1);
forced vital capacity (FVC); FEV1/FVC; mid-
expiratory flow between 25% and 75% FVC (FEF25e75);
(3) ventilation distribution (single and multiple breath
washout tests): from MBW we derived indices of
acinar and conductive airway ventilation heteroge-
neity (Sacin and Scond respectively) and lung clear-
ance index (LCI); from the single breath washout,
closing capacity (CC) was obtained;
(4) impulse oscillometry (IOS): from continuous impulse
oscillometry recordings during steady breathing, four
parameters were averaged over 5 breathing cycles:
resistance 5 Hz and 25 Hz (R5, R25), reactance at 5 Hz
(X5) and resonance frequency (fres);
(5) body plethysmography: ratio of residual volume and
total lung capacity (RV/TLC) and specific conduc-
tance (sGaw);Statistical analysis
Two-way ANOVA (within: visit; between: group) was per-
formed to detect differences in ACT scores and all lung
function parameters between groups and across visits using
Statistica 5.1 (StatSoft, Tulsa, OK). Significance was
accepted at p Z 0.05.Results
Sixty-six patients had to be screened to include 35 eligible
patients with baseline Sacin above the cut-off; of these 35
patients, 31 (15 male, 16 female) completed the study.
Three patients had dropped out because of an exacerbation
requiring oral corticosteroids (2 from the control arm, and 1
from the fine particle iCS arm) and a fourth patient because
of technical failure during the baseline visit. The final study
population consisted of 31 patients, with an average age of
52  17(SD) years, an average post bronchodilator FEV1
84  17(SD) %predicted and Sacin of 165  69(SD) %pre-
dicted. Twenty six out of 31 patients were atopic. Sixteen
patients were randomized to the control group (BUD-DPI)
and 15 to the study group (BDP-HFA). There were no
baseline differences in anthropometric data, maintenance
iCS dose and ACT score between both groups (Table 1).
None of the lung function parameters, except for FEV1/FVC
(p Z 0.04), showed any baseline difference between both
treatment arms.
Six and 12 weeks after randomization, no significant
changes in any index of large or small airways function had
occurred in either study group (Tables 1e3) and asthma
control was maintained in both groups (Table 1). In
particular, with 15 patients in the fine particle treatment
and the measurement variability obtained here, this study
was powered (aZ 0.05; bZ 0.10) to detect a reversibility
of acinar abnormality of 25%predicted. This is approxi-
mately half of the reversibility required to obtain normal
Sacin values in the patient population under study,
considering that baseline Sacin was approximately 150%
pred in the fine particle iCS group.
By design, Sacin was elevated at baseline (Table 1).
While not being primary variables, the impulse oscillometry
indices also reflect some degree of structural abnormality
at baseline. For instance, the median R5 value for the
entire group (0.41 kPa L1 s) was close to the recently re-
ported ULN [14] applied to our age group (0.43 kPa L1 s);
the corresponding predicted median value was
0.25 kPa L1 s. Another parameter thought to primarily
reflect the smaller airways, i.e., the frequency dependence
of resistance (R5eR25), fell within the normal range in our
study group, but was almost double the predicted median
value. Indeed, our median value of R5eR25 for the entire
group at baseline was 0.061 kPa L1 s, compared to the
predicted median (0.035 kPa L1 s) and ULN
(0.115 kPa L1 s) reported for R5eR20 (R20 and R25 are
almost indistinguishable). Finally, the median X5 for our
study group (0.10 kPa L1 s) was relatively close to the
predicted median value (0.083 kPa L1 s) with
LLN Z 0.143 kPa L1 s. Taken together, these impulse
oscillometry indices do indicate a mild degree of peripheral
structural alterations at baseline, consistent with MBW
indices Sacin and Scond. The fact that neither of these
indices show any significant change after treatment, con-
firms the absence of structural change with treatment at
any level of the airway tree.
Besides the mechanical structural abnormalities
observed by MBW and IOS indices, the inflammatory pa-
rameters, i.e., bronchial NO production and alveolar NO
concentration, were entirely normal in either study group









Age (years) 55 [39e63] 51 [35e65]
height (cm) 172 [161e179] 168 [163e174]
weight (kg) 66 [57e73] 63 [59e70]
dose (BUD equiv) (mg) 800 [400e800] 800 [506e800]
ACT Baseline 23.0 [20.0e24.4] 23.0 [21.0e24.0]
ACT 6 Weeks 23.5 [20.6e25.0] 23.0 [21.0e24.7]
ACT 12 Weeks 23.0 [21.0e25.0] 24.0 [21.3e24.0]
Spirometry
Pre-dil FEV1 (%pred) baseline 72 [62e87] 84 [76e95]
6 weeks 74 [61e88] 84 [74e98]
12 weeks 77 [65e83] 84 [71e99]
Post-dil FEV1 (%pred) baseline 82 [70e94] 91 [78e102]
6 weeks 86 [70e92] 86 [77e103]
12 weeks 83 [72e96] 91 [76e106]
FVC (%pred) baseline 111 [105e118] 109 [87e118]
6 weeks 109 [104e115] 107 [90e121]
12 weeks 109 [102e118] 109 [91e120]
FEV1/FVC (%) baseline 64 [55e68] 72 [64e76]
6 weeks 64 [53e68] 73 [61e76]
12 weeks 65 [56e70] 72 [64e75]
FEF25e75% (%pred) baseline 36 [26e55] 52 [39e72]
6 weeks 35 [23e52] 45 [39e72]
12 weeks 41 [28e53] 50 [42e72]
ACT: Asthma Control Test score; Pre-dil FEV1: pre-bronchodilation Forced Expiratory Volume in 1 s; Post-dil FEV1: post-bronchodilation
Forced Expiratory Volume in 1 s; FVC: Forced Vital Capacity; FEF25e75%: forced expiratory flow between 25% and 75% of vital capacity.
1604 S. Hanon et al.(Table 2) and did not change with treatment. In particular,
the values for bronchial NO production and alveolar NO
concentration obtained here fall within the ranges of
normal obtained in a recent compilation [5] while the
FENO50 values are well below the cut-off reported for
identifying patients with eosinophilic airway inflammation
[15].Discussion
In this group of asthma patients with an average post
bronchodilator FEV1 of 84%pred, and with a maintenance
dose of maximum 800 mg BUD equivalent, the baseline ab-
normality of acinar ventilation heterogeneity could not be
significantly improved by reducing inhaled steroid particle
size. The patients selected for this study according to their
baseline acinar abnormality were not severe asthmatics, as
their asthma was controlled under a low or medium dose of
inhaled steroids [8]. We therefore expected that a signifi-
cant reversibility to normal could be achievable with a
small particle iCS. Considering the power analyses per-
formed for this study, any clinically meaningful reversibility
of acinar ventilation heterogeneity towards normality
should have been detected. Therefore we must conclude
that for the asthma patients under study here in their best
possible state (after bronchodilation), no improvement of
their abnormal acinar ventilation heterogeneity could be
obtained by changing steroid particle size only.This negative study with respect to the primary outcome
variable Sacin was confirmed by various other parameters
(displayed across Tables 1e3) that may not be directly
related, but that also potentially reflect changes in the
most peripheral air spaces [7]. None of the alternative
small airway parameters such as FEF25e75, RV/TLC, R5eR25,
alveolar NO measured here indicated any marked
improvement or deterioration of peripheral lung function
when switching to a fine particle inhaled steroid formula-
tion. Several of these indices of small airway function
intrinsically suffer from a lack of specificity, since they are
also influenced to some extent by the larger airways. Yet,
their sensitivity also implies that when no change is
observed in these small airway indices, it is highly probable
that no changes in the small airways have occurred (taking
into account the magnitude of change for which the study is
powered with respect to any particular small airway
parameter).
Given that in asthma, disease severity appears to be
correlated specifically with acinar ventilation heterogene-
ity [3], it may be important to target any abnormality of
ventilation distribution in the acinar zone at an early stage,
before patients develop symptoms. The otherwise stable
asthma population under study, with a clear-cut acinar
abnormality, was eligible for such targeting as was done
here by decreasing particle size. The interpretation of the
results in the present study then depends on the clinical
angle one wants to adopt. On the one hand, it may be
deceiving to observe that small steroid particles were









Sacin (%pred) Baseline 162 [130e221] 149 [117e167]
6 Weeks 137 [114e244] 131 [117e154]
12 Weeks 158 [115e212] 141 [113e158]
Scond (%pred) Baseline 137 [114e216] 139 [113e172]
6 Weeks 171 [114e202] 134 [125e182]
12 Weeks 172 [118e220] 127 [95e191]
LCI (%pred) Baseline 106 [103e115] 103 [99e109]
6 Weeks 111 [106e118] 108 [102e110]
12 Weeks 106 [103e110] 105 [99e110]
SBW CC (%) Baseline 23 [15e28] 20 [16e26]
6 Weeks 22 [20e32] 22 [18e28]
12 Weeks 24 [17e31] 20 [16e24]
Exhaled NO
Bronchial NO production (uncorrected) (pl/s) Baseline 892 [436e1335] 617 [410e1591]
6 Weeks 739 [508e1235] 654 [510e1276]
12 Weeks 716 [511e1178] 644 [420e1561]
Alveolar NO (uncorrected) (ppb) Baseline 2.5 [2.0e3.5] 1.9 [1.6e2.4]
6 Weeks 2.1 [1.7e2.5] 2.2 [1.9e3.2]
12 Weeks 2.8 [1.9e3.8] 2.4 [1.6e3.0]
Alveolar NO corr (back diff corrected) (ppb) Baseline 1.7 [1.0e2.2] 1.0 [0.8e1.3]
6 Weeks 1.3 [0.5e1.8] 1.5 [0.6e2.1]
12 Weeks 1.5 [1.0e2.4] 1.3 [0.7e2.0]
FENO50 (ppb) Baseline 13.2 [9.5e20.3] 10.4 [7.7e22.7]
6 Weeks 12.1 [8.4e18.5] 10.4 [9.0e20.1]
12 Weeks 11.6 [8.7e19.8] 9.9 [8.8e23.0]
Sacin: acinar ventilation heterogeneity; Scond: conductive ventilation heterogeneity; LCI: Lung Clearance Index, SBW CC: Single Breath
nitrogen washout derived Closing Capacity.
NO: Nitric Oxide; FENO50: exhaled nitric oxide measured at 50 ml s
1.
Acinar airway abnormality in asthma 1605unable to reduce acinar ventilation heterogeneity in these
asthma patients. This begs the question of whether this
residual small airway dysfunction is irreversible by steroids
at all, or whether it is the inhaled route that is ineffective
to normalize the most peripheral airway alterations. On the
other hand, it is interesting and indeed somewhat surpris-
ing, to observe that in patients titrated to low or moderate
steroid doses to maintain clinical stability, steroid particle
size per se does not appear to matter.
When considering equivalence of steroid doses at the
basic receptor level, relative potency of budesonide and
beclomethasone is 0.75 [16] giving a small potential
advantage in favour of the reference medication at the
dosages delivered here. Hence, the effect of aerosol
formulation and aerosol delivery superimposed upon the
receptor potency appears to be such that lung function
down to the small airway level is maintained. Since exhaled
NO parameters also remained unchanged (Table 2) either
formulation appears to contain sufficient drug dose to
suppress eosinophilic inflammation throughout the lungs.
Considering the particle sizes that have been reported for
the reference medication [mass median aerodynamic
diameter (MMAD) of 2.3 mm at 60 L min1] [17] and for the
beclomethasone ultrafine particle formulation (MMAD
w1.0 mm with geometric standard deviation around 2.5)[18], there must be an overlap in the size distribution which
contains the portion of drug dose that is critical to thera-
peutic efficacy. This could imply that the larger particles in
the size distribution of the reference medication are
redundant, potentially producing local side effects via
oropharyngeal deposition [19]; for BDP-HFA, oropharyngeal
deposition is relatively low [20].
Several studies by other groups have also aimed to
reduce structural or functional abnormality in the lung
periphery of asthma patients by treatment with small
particle steroid formulations, yielding sometimes conflict-
ing results. For instance, computed tomography studies
have shown a decrease in air trapping with fine particle
HFA-BDP in comparison with chlorofluorocarbon BDP (CFC-
BDP), but not in comparison with fluticasone propionate
[21,22]. In a 12 weeks open label study HFA-BDP improved
all studied IOS indices, whereas CFC-BDP increased all the
indices except R5eR20 (thought to reflect small airways
resistance) [23]. After 8 weeks, ciclesonide improved IOS
indices of small airway function compared with fluticasone
propionate in mild asthma [24]. For an exhaustive overview
of studies on small particle aerosols in asthma specifically
investigating small airways function, we refer to van den
Berge et al. [25]; for particle sizes involved to Leach et al.
[26]. Taken together, previous studies indicate that partial









RV/TLC (%) Baseline 37 [29e44] 31 [24e38]
6 Weeks 37 [25e44] 31 [24e41]
12 Weeks 40 [28e43] 32 [24e39]
sGaw (L/s/cmH2O/L) Baseline 0.070 [0.058e0.090] 0.085 [0.069e0.109]
6 Weeks 0.069 [0.052e0.102] 0.084 [0.066e0.111]
12 Weeks 0.071 [0.050e0.090] 0.093 [0.068e0.111]
Impulse oscillometry
R5 (kPa L
1 s) Baseline 0.50 [0.32e0.57] 0.37 [0.30e0.53]
6 Weeks 0.48 [0.35e0.61] 0.36 [0.30e0.47]
12 Weeks 0.53 [0.37e0.60] 0.37 [0.33e0.49]
R25 (kPa L
1 s) Baseline 0.39 [0.29e0.43] 0.32 [0.28e0.36]
6 Weeks 0.36 [0.31e0.41] 0.29 [0.26e0.33]
12 Weeks 0.37 [0.30e0.44] 0.32 [0.26e0.34]
R5eR25 (kPa L
1 s) Baseline 0.078 [0.033e0.200] 0.039 [0.020e0.162]
6 Weeks 0.095 [0.045e0.202] 0.044 [0.024e0.170]
12 Weeks 0.096 [0.062e0.179] 0.051 [0.024e0.179]
X5 (kPa L
1 s) Baseline 0.10 [(0.27)e(0.07)] 0.10 [(0.17)e(0.07)]
6 Weeks 0.12 [(0.33)e(0.07)] 0.09 [(0.17)e(0.07)]
12 Weeks 0.12 [(0.22)e(0.07)] 0.09 [(0.15)e(0.07)]
Resonance frequency (Hz) Baseline 12.6 [10.9e16.0] 11.4 [9.6e16.5]
6 Weeks 14.9 [11.4e19.1] 11.9 [10.0e15.5]
12 Weeks 13.0 [11.6e18.0] 11.7 [9.6e16.0]
RV/TLC: Residual Volume/Total Lung Capacity ratio; sGaw: specific airways conductance; R5: resistance at 5 Hz; R20: resistance at 25 Hz;
R5eR25: absolute difference of R5 and R25; X5: reactance at 5 Hz.
1606 S. Hanon et al.reversibility can be obtained in the small airways, but that
the actual effect of inhaled steroid particle size is some-
times difficult to discern, also depending on the outcome
measure used.
In the present study, we have deliberately studied the
asthma patients post-bronchodilation, and we have isolated
the steroid from the LABA in a separate inhaler, to study
the effect of steroid particle size alone, all other things
being equal. The absence of change in any of the small
airway parameters in our study can be set against our
previous study [4] where a significant but relatively modest
reversibility of acinar heterogeneity (of 20% pre-dilation
and 15% post-dilation) was obtained in a group of asthma
patients with an average baseline Sacin abnormality which
was approximately double that in the patients under study
here (the post-dilation baseline value for the study popu-
lation in [4] would correspond to w230%pred). In that
study, the fine particle iCS dose was double that used here
in the first 6 weeks when most of the effect was observed,
before switching to half the iCS dose. Our recruitment
strategy for the present study, requesting only that Sacin
was above a certain threshold and limited to patients on
less than 800 mg BUD equivalent, resulted in a lower median
Sacin in this study of 149%pred (162%predicted in the con-
trol arm). It could be argued on basis of the alveolar NO
obtained here e not measured in [4] e that the most pe-
ripheral inflammatory component was already treated in
the patients included in the present study, and that any
change in particle size would not affect Sacin. In fact,Scond remained unaffected too, as was expected from our
previous study [4].
We suspect that the residual Sacin abnormality observed
in these well controlled asthma patients, constituting more
or less 50% of the stable asthma population on less than
800 mg BUD equivalent screened, is in fact a reflection of a
non-steroid responsive inflammatory process that remains
untreated in the lung periphery. This hypothesis can be
brought in line with recent data by McGrath et al. [27] who
observed that only 36% of mild-to-moderate asthma pa-
tients not treated with an iCS and 17% of patients on iCS
have sputum eosinophilia, and that the subgroup with the
persistent non-eosinophilic phenotype responds poorly to
currently available asthma controller medications in terms
of airflow obstruction. In specific relation to the age of the
patients participating in our study (average:52years), it is
worth mentioning a very recent report of an association
between greater% sputum neutrophils and greater acinar
ventilation heterogeneity in asthma patients aged >40
years [28]. Also, asthma in older adults has been reported
to be characterized more frequently by irreversible airway
obstruction [29].
In conclusion, reversibility of the acinar airway abnor-
mality could not be achieved after a switch to a fine par-
ticle ICS formulation in asthma patients with well
controlled asthma. We suspect that this acinar abnormality,
present at baseline despite good asthma control under iCS
treatment, persists under the fine particle iCS because it
might not be caused by active eosinophilic inflammation or
Acinar airway abnormality in asthma 1607not be a reversible inflammatory process at all. Alternative
treatment strategies targeting the small airways should
include characterization of the asthma patient in terms of
peripheral airway function and inflammation at baseline, to
identify those patients who can benefit from any such
treatment at all.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.rmed.2014.07.019.
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